palo alto
-
A One-Time Treatment for NASH? Kriya Strikes Deal for Liver Disease Gene Therapy
Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.
-
BMS builds on BridgeBio alliance, inking deal for rights to KRAS cancer drug
Bristol Myer Squibb is getting rights to BBP-398, a contender in the chase for drugs that address difficult-to-target KRAS mutations. Meanwhile, BridgeBio Pharma receives some needed cash as it restructures in the wake of the Phase 3 failure of its lead program late last year.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Regenerative med biotech ProKidney inks merger to get $825M for CKD cell therapy
ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
-
Heart drug’s trial failure busts bid to best Pfizer, but BridgeBio still bets on coming data
BridgeBio reported its drug acoramidis missed the main goal of a pivotal study in patients with transthyretin amyloidosis affecting the heart—the same type of patients helped by a currently approved blockbuster Pfizer drug. BridgeBio attributed the trial failure to a surprisingly strong placebo response, and it will continue the study, hoping for better outcomes on additional goals.
-
Decentralized clinical trials platform Medable now valued at $2.1B
Medable recently raised $304 million, its fourth funding round in the past two years. The company’s software can be used to virtually consent patients into clinical trials and run telehealth visits as part of a trial.
-
GV leads $72M investment in startup offering virtual behavioral healthcare for kids
Brightline focuses on providing virtual behavioral health solutions for kids. The startup plans to put the new funds to use by launching a coaching platform for families and to expand its services to more companies and health plans.
-
BridgeBio turns Alexion asset into first approved drug for rare metabolic disease
The FDA decision makes Nulibry the first drug approved to treat MoCD type A, a rare metabolic disease. It’s also the first FDA-approved product for rare disease drug developer BridgeBio Pharma.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Devices & Diagnostics, Health Tech
Limbix digital therapeutic for adolescent mental health finds niche amid Covid-19 pandemic
The Silicon Valley startup plans to start its registration-directed study of Limbix Spark in the earlier part of next year and – if successful – would anticipate FDA clearance in early 2022.
-
CareTribe finds caregivers need support, too
The Palo Alto-based startup provides tools to support family caregivers, and uses predictive analytics to help them develop personalized action plans.
-
Decentralized clinical trials won’t slow down after Covid-19 pandemic ends
In a interview, an executive from Medable said patients will likely demand to have the choice of whether to show up at trial sites or participate in studies remotely. The Covid-19 pandemic has accelerated a trend toward decentralized trials that was already underway before it began.
-
How Covid-19 is accelerating adoption of decentralized clinical trials
Late last month, Medable and LabCorp CRO Covance signed a deal to accelerate adoption of decentralized trials, a trend that has been helped along as Covid-19 has created challenges to conducting trials dependent on traditional brick-and-mortar sites.
-
Asset Management Ventures raising for $150M fund
Asset Management Ventures, a Silicon Valley-based health tech investment firm, is raising $150 million for a new fund, according to financial documents.
-
Startup seeks to hold doctors, hospitals accountable on patient record requests
Ciitizen, based in Palo Alto, California, published a report card that uses a five-star system to rate how health care providers comply with federal rules governing record requests.